**Author details**

Fabio Arturo Iannotti Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, NA, Italy

\*Address all correspondence to: fabio.iannotti@icb.cnr.it

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**97**

*Pharmacological Actions and Potential Therapeutic Use of Cannabinoids in Duchenne's…*

Prospects for treatment. Current Diabetes Reports. 2008;**8**:12-19

[10] Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;**51**:1356-1367

[11] Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: Role in neuroinflammatory and neurodegenerative disorders. CNS & Neurological Disorders Drug Targets.

[12] Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters.

[13] Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep ob/Lep ob mice. International Journal of Obesity.

[9] Di Marzo V. CB1 receptor antagonism: Biological basis for metabolic effects. Drug Discovery

Today. 2008;**13**:1026-1041

2010;**9**:564-573

1994;**350**:240-244

2005;**29**:183-187

2007;**364**:105-110

[14] Cavuoto P, McAinch AJ,

[15] Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Molecular and Cellular Endocrinology. 2007;**267**:63-69

[16] Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT,

Hatzinikolas G, Janovská A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochemical and Biophysical Research Communications.

*DOI: http://dx.doi.org/10.5772/intechopen.85131*

[1] Di Marzo V, Bifulco M, De Petrocellis

[2] Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.

[3] Iannotti FA, Piscitelli F, Martella A, Mazzarella E, Allarà M, Palmieri V, et al. Analysis of the & quot; endocannabinoidome& quot; in peripheral tissues of obese Zucker rats. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2013;**89**:127-135

[4] Iannotti FA, Di Marzo V,

Research. 2016;**62**:107-128

[6] Di Marzo V, Wang J.

ISBN: 9780124201262

2016;**40**:210-219

[8] Perkins JM, Davis SN.

and the metabolic syndrome:

2018;**71**:1-17

Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in

neurological disorders. Progress in Lipid

[5] Baggelaar MP, Maccarrone M, van der Stelt M. 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain. Progress in Lipid Research.

Endocannabinoidome: The World of Endocannabinoids and Related Mediators. Academic Press; 19

[7] Gatta-Cherifi B, Cota D. New insights on the role of the endocannabinoid system in the regulation of energy balance. International Journal of Obesity.

September 2014. ISBN: 9780128004296,

Endocannabinoid system overactivity

L. The endocannabinoid system and its therapeutic exploitation. Nature Reviews. Drug Discovery.

**References**

2004;**3**:771-784

2012;**367**:3216-3228

*Pharmacological Actions and Potential Therapeutic Use of Cannabinoids in Duchenne's… DOI: http://dx.doi.org/10.5772/intechopen.85131*
